ADMA Biologics (NASDAQ:ADMA) Cut to “Hold” at Wall Street Zen

ADMA Biologics (NASDAQ:ADMA) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts have also issued reports about the company. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Mizuho decreased their target price on ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating for the company in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $28.00.

ADMA Biologics Price Performance

ADMA opened at $11.01 on Friday. The business has a fifty day moving average of $13.45 and a 200 day moving average of $15.80. ADMA Biologics has a 52-week low of $7.21 and a 52-week high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The stock has a market cap of $2.62 billion, a P/E ratio of 18.35 and a beta of 0.82.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the previous year, the business earned $0.46 EPS. ADMA Biologics’s revenue was up 18.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that ADMA Biologics will post 0.51 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steve Elms purchased 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ADMA. Boothbay Fund Management LLC purchased a new position in ADMA Biologics during the 3rd quarter worth $11,334,000. Thrivent Financial for Lutherans grew its stake in ADMA Biologics by 24.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock worth $60,719,000 after buying an additional 826,415 shares during the last quarter. American Century Companies Inc. grew its stake in ADMA Biologics by 1.8% during the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after buying an additional 84,934 shares during the last quarter. Renaissance Group LLC grew its stake in ADMA Biologics by 50.4% during the 3rd quarter. Renaissance Group LLC now owns 516,588 shares of the biotechnology company’s stock worth $7,573,000 after buying an additional 173,016 shares during the last quarter. Finally, Tealwood Asset Management Inc. purchased a new position in ADMA Biologics during the 4th quarter worth $1,315,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.